Got $1,000? 3 High-Yield Healthcare Stocks to Buy and Hold Forever.

The article analyzes three healthcare-related dividend stocks—Kenvue (KVUE), Medtronic (MDT), and Pfizer (PFE)—each offering distinct investment profiles. Kenvue, a consumer staples spin-off from J&J, presents a 5.5% dividend yield following a stock price dip due to Tylenol-related concerns and lowered 2025 guidance, yet maintains a strong brand portfolio. Medtronic, a medical device company, is nearing Dividend King status with 48 years of increases, and its strategic diabetes division spinoff is expected to enhance profitability and growth, currently yielding around 3%. Pfizer offers the highest yield at nearly 7% but faces considerable risk from a high payout ratio, potential dividend cut post-Metsera acquisition, and patent expirations, though the acquisition is viewed as a strategic move to bolster its pipeline, positioning it as a high-risk turnaround play.

Analysis

Kenvue, Medtronic, and Pfizer present distinct investment profiles within the healthcare sector, offering varying risk-reward dynamics for dividend-focused investors. Kenvue, a consumer staples spin-off from Johnson & Johnson, currently offers a 5.5% dividend yield, driven by a stock price decline following negative attention on its Tylenol brand and lowered 2025 guidance. Despite these headwinds, its portfolio of iconic brands suggests long-term resilience.

Medtronic, a medical device leader, is nearing "Dividend King" status with 48 consecutive years of dividend increases, and its 3% yield is historically elevated. The company's planned diabetes division spinoff is strategically designed to be instantly accretive to earnings, focusing on higher-margin businesses to drive future growth, though Wall Street maintains a cautious "show-me" attitude.

Pfizer presents the highest yield at nearly 7%, but this comes with significant risk due to a payout ratio near 100% and potential for a dividend cut, similar to its post-Wyeth acquisition history. The ongoing Metsera acquisition and upcoming patent expirations add to uncertainty, yet the acquisition is viewed as a strategic move to replenish its drug pipeline, positioning Pfizer as a high-risk turnaround opportunity.

Key Decisions for Investors

• Investors should monitor Kenvue's brand sentiment and 2025 guidance for potential entry, leveraging its strong consumer staples portfolio despite current challenges.
• For Medtronic, evaluate the execution of its diabetes division spinoff and its impact on earnings accretion, as this is key to its growth trajectory and dividend reliability.
• Pfizer requires careful consideration of its high dividend yield against the significant risk of a cut due to its high payout ratio and strategic acquisitions, positioning it as a high-risk, high-reward turnaround opportunity.